Asia
Jenscare Scientific Expects Revenue to Jump Up to 400% in H1
Jenscare Scientific (HKG:9877) expects to generate about 63 million yuan to 65 million yuan in revenue for the first half of 2026, up about 385% to 400% from the same period a year earlier, according to a Monday Hong Kong bourse filing.The company attributed the expected growth mainly to stronger commercialization of its Ken-Valve transcatheter aortic valve replacement system and increased overseas clinical use of its structural heart interventional products.Jenscare expects to release its interim results in August.
HKG:9877
